Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Hematology Am Soc Hematol Educ Program ; 2023(1): 737-744, 2023 Dec 08.
Article in English | MEDLINE | ID: mdl-38066933

ABSTRACT

Hematologists are often needed to assist with the management of microangiopathic emergencies in pregnancy. A firm understanding of the diagnosis and management of preeclampsia with severe features, hemolysis elevated liver enzyme and low platelet syndrome, and disseminated intravascular coagulation, which are the most common causes of microangiopathic emergencies, is critical. However, being able to consider when other microangiopathic emergencies (acute fatty liver of pregnancy, congenital and acquired thrombotic thrombocytopenic purpura, complement mediated microangiopathy, antiphospholipid syndrome) should be considered is imperative. The hematologist and obstetric team should work together to optimize the care of common as well as rare hematologic emergencies.


Subject(s)
HELLP Syndrome , Hemolytic-Uremic Syndrome , Pre-Eclampsia , Purpura, Thrombotic Thrombocytopenic , Pregnancy , Female , Humans , HELLP Syndrome/diagnosis , HELLP Syndrome/therapy , Pre-Eclampsia/diagnosis , Pre-Eclampsia/therapy , Emergencies , Purpura, Thrombotic Thrombocytopenic/diagnosis , Hemolytic-Uremic Syndrome/diagnosis
2.
Am J Perinatol ; 37(8): 809-812, 2020 06.
Article in English | MEDLINE | ID: mdl-32274772

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations. KEY POINTS: · Corticosteroid use is an important part of prematurity treatment because it provides benefit to the fetus.. · Corticosteroid use may be related with increased morbidity and mortality in novel coronavirus disease 2019 (COVID-19).. · Therefore, during the COVID-19 pandemic, an alteration in current corticosteroid practices is necessary to uniquely weigh the maternal risks and fetal benefits..


Subject(s)
Betamethasone , Coronavirus Infections , Dexamethasone , Fetal Organ Maturity/drug effects , Pandemics , Pneumonia, Viral , Pregnancy Complications, Infectious , Premature Birth/prevention & control , Prenatal Care/methods , Betacoronavirus/isolation & purification , Betamethasone/administration & dosage , Betamethasone/adverse effects , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Female , Gestational Age , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Pregnancy , Pregnancy Complications, Infectious/therapy , Pregnancy Complications, Infectious/virology , Risk Assessment , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL